Aggressive blood pressure lowering is dangerous: The J-curve: Con side of the argument

Hypertension

Volumn 63, Issue 1, 2014, Pages 37-40

  Verdecchia, Paolo ^a   Angeli, Fabio ^b   Mazzotta, Giovanni ^a   Garofoli, Marta ^a   Reboldi, Gianpaolo ^b  

^a Ospedale di Assisi   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; HEART INFARCTION; HUMAN; HYPERTENSION; INTERVENTION STUDY; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; PATIENT CODING; POST HOC ANALYSIS; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; KIDNEY DISEASES;

EID: 84891625589     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01018     Document Type: Article

References (26)

1. E gan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046-1058
2. Cruickshank J. The J-curve in hypertension. Curr Cardiol Rep. 2003;5:441-452
3. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: Exactly how essential? J Am Coll Cardiol. 2009;54:1827-1834
4. Williams B. Hypertension and the "J-curve". J Am Coll Cardiol. 2009;54:1835-1836
5. Zanchetti A. Blood pressure targets of antihypertensive treatment: Up and down the J-shaped curve. Eur Heart J. 2010;31:2837-2840
6. Cruickshank JM. Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther. 2000;14:373-379
7. Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, Leonetti G, Tuomilehto J, Yodfat Y. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167:1884-1891
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913
9. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18
10. O vbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM; PRO FES Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011;306:2137-2144
11. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, Macmahon S, Neal B; PRO GRES Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: The PRO GRES trial. J Hypertens. 2006;24:1201-1208
12. Anderson TW. Re-examination of some of the Framingham blood-pressure data. Lancet. 1978;2:1139-1141
13. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884-893
14. R abkin SW, Waheed A, Poulter RS, Wood D. Myocardial perfusion pressure in patients with hypertension and coronary artery disease: Implications for DBP targets in hypertension management. J Hypertens. 2013;31:975-982
15. P olese A, De Cesare N, Montorsi P, Fabbiocchi F, Guazzi M, Loaldi A, Guazzi MD. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation. 1991;83:845-853
16. Kai H, Ueno T, Kimura T, Adachi H, Furukawa Y, Kita T, Imaizumi T; CREDO-Kyoto Investigators. Low DBP may not be an independent risk for cardiovascular death in revascularized coronary artery disease patients. J Hypertens. 2011;29:1889-1896
17. Davis EM, Appel LJ, Wang X, Greene T, Astor BC, Rahman M, Toto R, Lipkowitz MS, Pogue VA, Wright JT Jr; African American Study of Kidney Disease and Hypertension Research Collaborative Group. Limitations of analyses based on achieved blood pressure: Lessons from the African American study of kidney disease and hypertension trial. Hypertension. 2011;57:1061-1068
18. S leight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET Investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27:1360-1369
19. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC; Treating to New Targets Steering Committee and Investigators. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897-2908
20. Dorresteijn JA, van der Graaf Y, Spiering W, Grobbee DE, Bots ML, Visseren FL; Secondary Manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension. 2012;59:14-21
21. S taessen J, Bulpitt C, Clement D, De Leeuw P, Fagard R, Fletcher A, Forette F, Leonetti G, Nissinen A, O'Malley K. Relation between mortality and treated blood pressure in elderly patients with hypertension: Report of the European Working Party on High Blood Pressure in the Elderly. BMJ. 1989;298:1552-1556
22. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP; INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. J-shaped relationship between blood pressure and mortality in hypertensive patients: New insights from a meta-analysis of individualpatient data. Ann Intern Med. 2002;136:438-448
23. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;45:907-913
24. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665
25. Lv J, Neal B, Ehteshami P, Ninomiya T, Woodward M, Rodgers A, Wang H, MacMahon S, Turnbull F, Hillis G, Chalmers J, Perkovic V. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: A systematic review and meta-analysis. PLoS Med. 2012;9:e1001293
26. R eboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Blood pressure lowering in diabetic patients. J Hypertens. 2012;30:438-439